Global Uveitis Treatment MarketReport, published by Variant Market Research, forecast that the global market is expected to reach $1,142 Million by 2024 from $638 Million in 2016, growing at a CAGR of 7.5% from 2016 to 2024. By geography, Asia-Pacific and RoW are expected to grow at a CAGR of 8.0% and 7.9%, respectively, during the forecast period.
"Uveitis Treatment Market (By Type: Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, And Panuveitis; By Treatment Type: Anti-Inflammatory Medications, Antibiotic/Antiviral Medications, And Immunosuppressive Medications; By Geography: North America, Europe, Asia-Pacific, and RoW) Global Scenario, Market Size, Outlook, Trend and Forecast, 2015-2024"
Some of the factors driving the growth of the global uveitis treatment market includes growing incidences of uveitis disease, expansion of generic drug market, and rising R&D investments. Though, lack of knowledge, possibility of side effects caused by medication, and high costs would limit the adoption among consumers. Furthermore, new product development and rising consumer awareness is anticipated to provide growth opportunities in the forecast period.
Type, treatment type, and geography are the major bifurcations considered in the global uveitis treatment market. Type is segmented into anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis. Among which, anterior uveitis and posterior uveitis held the majority of the share in 2016. Treatment type segment is further categorized into anti-inflammatory medications, antibiotic/antiviral medications, and immunosuppressive medications. Anti-inflammatory medications accounted the major share in 2016, whereas, antibiotic/antiviral medications will dominate the segment with fastest CAGR.
By geography, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW). North America accounted the maximum share with 38.9% in 2016, driven by, growing number of clinical trials, and increasing budgets for R&D by several research organizations and pharmaceutical companies, followed by Europe with 28.7%. In terms of growth Asia-Pacific is likely to dominate with fastest CAGR, owing to, increasing number of elderly population, and rise in number of people suffering from autoimmune disorders.
Major market players comprise Novartis AG (ALCON), Valeant Pharmaceutical International Inc., EyeGate Pharmaceuticals Inc., Alimera Sciences Inc., Santen pharmaceutical Co., Ltd., Bausch & Lomb Incorporated., AbbVie Inc., Allergan Inc., Amdipharm Mercury Company Ltd., and pSivida Corp., among others.